Research groups
Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
Treating the side effects of exogenous glucocorticoids; Can we separate the good from the bad?
Journal article
Pofi R. et al, (2023), Endocr Rev
-
A low-energy total diet replacement programme demonstrates a favourable safety profile and improves liver disease severity in non-alcoholic steatohepatitis
Journal article
KOUTOUKIDIS D. et al, (2023), Obesity
-
Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations.
Journal article
De Alcubierre D. et al, (2023), J Endocrinol Invest
-
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept, randomized double-blind placebo-controlled trial
Journal article
TOMLINSON J., (2023), Nature Communications
-
Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent.
Journal article
Colosimo S. et al, (2022), Nutr Metab Cardiovasc Dis